lofexidine   Click here for help

GtoPdb Ligand ID: 9868

Synonyms: BritLofex® | Lucemyra®
Approved drug
lofexidine is an approved drug (UK (1990), FDA (2018))
Compound class: Synthetic organic
Comment: Lofexidine is a selective α2-adrenoceptor agonist [1]. The INN defines this drug as a racemic mixture of stereo isomers. We show the chemical structure without specified stereochemistry to represent the mixture. Oral lofexidine tablets contain the hydrochloride salt.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 33.62
Molecular weight 258.03
XLogP 3.14
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(C1=NCCN1)Oc1c(Cl)cccc1Cl
Isomeric SMILES CC(C1=NCCN1)Oc1c(Cl)cccc1Cl
InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
No information available.
Summary of Clinical Use Click here for help
In the UK lofexidine is administered to relieve symptoms in patients undergoing opioid detoxification. It is the first non-opioid to be used for managing opioid withdrawal symptoms. The US FDA approved its use in May 2018. Its use is not yet approved by the EMA (May 2018).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Lofexidine mitigates the acute and painful symptoms of opioid withdrawal by suppressing the norepinephrine surge that produces the symptoms. α2-adrenoceptor agonism reduces norepinephrine release.
External links Click here for help